**Introduction:**

Coronary artery aneurysms after coronary intervention are rare, the incidence of coronary artery aneurysms after DES implantation is low within the first 9 months, with a reported incidence of 0.2% to 2.3%, a rate similar to that reported after bare-metal stent (BMS) implantation (0.3% to 3.9%) in the DES versus BMS randomized trials. Most “aneurysms” are in fact pseudoaneurysms rather than true aneurysms. Residual dissection and deep arterial wall injury (rupture or resection of the vessel media) caused by oversized balloons or stents, high pressure balloon inflations, atherectomy, and laser angioplasty have all been associated with coronary artery aneurysms after coronary intervention. Drug-eluting stents (DES), which locally elute antiproliferative drugs, can dramatically inhibit neointimal growth, thereby suppressing restenosis, but at the same time potentially causing coronary aneurysms due to other mechanisms, such as delayed re-endothelialization, inflammatory changes of the medial wall, and hypersensitivity reactions. These findings may be due to delayed healing secondary to the antiproliferative action of the eluted drug, cell necrosis and/or apoptosis from the antimitabolite effect of the drug, and hypersensitivity reactions to the drug/polymer mixture on the DES. Systemic administration of anti-inflammatory agents (glucocorticoids and colchicine) after stent implantation may be associated with a greater risk of aneurysm formation. However, the true incidence, clinical course, and treatment of coronary artery aneurysms after DES implantation remain largely unknown.

**Case Report:**

Mr. X, 60 years old non smoker, non alcoholic, diabetic, hypertensive businessman got admitted in NICVD and was diagnosed as a case of Chronic Stable Angina. His ETT was strongly positive, CAG showed significant long lesion in LAD. Direct stenting with DES to LAD done and whole procedure was uneventful. After 10 days of PCI patient got readmitted in hospital with complaints of chest discomfort with high grade fever for 2 days. ECG showed AMI (Extensive Anterior) indicating involvement of LAD territory with strong suspicion of Sub Acute Stent Thrombosis (SAST). Streptokinase could not be given due to delayed arrival. Patient was treated conservatively with LMWH. Check CAG was done 7 days after readmission showing Patent stent in LAD with aneurysmal dilatation at the distal end of stent in LAD. The object of this case report is to focus on the rare but not uncommon incidence of stent implantation.
Discussion:
Coronary intervention-associated aneurysms usually are detected at the time of repeat angiography for recurrent symptoms or as part of routine angiographic follow-up as mandated by study protocols. Coronary angiography is the gold standard for the diagnosis of coronary aneurysms, which are defined as a luminal dilation 50% larger than that of the adjacent reference segment \(^3,11,12\). However, coronary angiography provides only luminal information and cannot visualize other structures, including the layers of the arterial wall. Further discrimination between true aneurysms and pseudoaneurysms, as well as detection of the aneurysm entry site (sometimes caused by stent edge dissection or stent edge injury at acute bends during vessel movement), are important to optimally manage aneurysms after coronary intervention. Intravascular ultrasound (IVUS) has become the “gold standard” in providing critical diagnostic information to address these anatomic considerations in the evaluation of coronary aneurysms \(^13-15\). Furthermore, other advanced coronary imaging techniques, such as computed tomography angiography, coronary magnetic resonance angiography, and real-time
3-dimensional echocardiography, also can be used as tools to detect and follow certain coronary aneurysms noninvasively 16–20, and computed tomography angiography may be the most effective of these in the milieu of metal stent artifacts 21. In addition to the mechanical risk factors for aneurysm formation that are observed with both BMS and DES, there are other potential mechanisms that may be specific to DES. Although inflammatory and allergic reactions to nickel and molybdenum have been reported after BMS implantation 22, the triggers for inflammatory and allergic reactions after DES implantation are more complex because DES consist of 3 components: the antistenotic drug, the drug carrier vehicle (polymer), and the stent platform. In particular, the polymer carrier has been shown to provoke eosinophilic/heterophilic infiltration and induce a marked inflammatory reaction of the arterial wall 8,23,24. In addition, delayed healing reactions in response to DES, such as incomplete endothelialization over DES struts, have been detected by invasive approaches (angiography and optical coherence tomography) as well as in autopsy studies 9,25–26. In short, the combination of physical trauma induced by stent implantation and specific biological reactions after DES implantation might together contribute to coronary aneurysm formation after DES implantation. In the DES versus BMS randomized trials, routine angiographic follow-up was performed in a large subset of patients at 6 to 9 months after the initial procedure. In this analysis, the incidence of coronary aneurysms was similar with DES compared with BMS. 1.1% with DES and 0.8% with BMS 5,6,27–29. Three different types of aneurysms after DES or BMS implantation have been described. Type I aneurysms is a type of aneurysm that demonstrates rapid early growth with pseudoaneurysm formation detected within 4 weeks 30,31. This type is typically complicated by clinical pericarditis. Given the rapid time course of aneurysm formation, it is likely that arterial injury related to the procedure is the likely contributor to aneurysm formation in these cases rather than the chronic arterial response to the stent, polymer, and drug. The second kind of aneurysm described in the literature is that with a “subacute to chronic” presentation (type II) and is typically detected incidentally during angiography for recurrent symptoms or as part of protocol mandated follow-up (usually detected 6 months after the procedure) 32–39. These aneurysms appear to have the most varied clinical presentations; some patients are asymptomatic, but some have complaints of angina. It seems more likely in this scenario that a chronic arterial response to a metal stent, polymer, and/or drug, may be the basis for aneurysm formation in this subtype.

The final reported subtype in the published literature is mycotic or infectious in etiology (type III) 40,41,42. Large mycotic aneurysms infected with Staphylococcus aureus after DES or BMS implantation have been reported. In these rare cases, patients typically present with systemic manifestations and fever as the result of bacteremia. Whether the local immunosuppressive effects of eluted drugs from stents tend to increase the incidence of these rare infectious aneurysms is unknown. Treatment of coronary aneurysms must be “individualized” considering the aneurysm size, expansion history, pathophysiology, and symptoms. For pseudoaneurysms detected by IVUS (type I) that are large at presentation (i.e., at least twice the reference vessel diameter) or show significant expansion over time, especially in the presence of symptoms, propose interventional or surgical treatment. Our threshold for treatment is lower for pseudoaneurysms than for true aneurysms, because of the presumed greater likelihood for rupture. For large true aneurysms (type II), again more than twice as large as the reference vessel diameter, especially with symptoms, we would also propose interventional or surgical treatment to avoid potential life threatening complications, regardless of stent type (BMS or DES). We propose immediate surgical therapy for any confirmed infected aneurysm (type III). Finally, long-term antithrombotic drug therapy, such as aspirin and clopidogrel, should be necessary to reduce the risk of stent thrombosis and distal embolism in patients with coronary artery aneurysms 43,44. Clearly, there is no consensus regarding the treatment algorithm and our proposal is not based on prospective data, underscoring the need for further study of this relatively infrequent phenomenon.

Conclusions: The clinical course of coronary artery aneurysms after DES implantation is variable. Some aneurysms naturally resolve, but some aneurysms can lead to life-threatening complications. Although the best treatment for coronary aneurysms after DES is controversial. Expanding pseudoaneurysms, infected aneurysms, and large, chronic (and expanding) aneurysms with symptoms should be treated.

References:


38. Kim JW, Seo HS, Suh SY, Rha SW, Park CG and Oh DJ. Spontaneous resolution of neoaneurysm following implantation of a paclitaxel eluting coronary stent. *Int J Cardiol* 2006;112:e12–3.


